Darcrus (DAR) Price Reaches $0.0900 on Exchanges

Darcrus (CURRENCY:DAR) traded flat against the US dollar during the 1 day period ending at 20:00 PM ET on June 23rd. One Darcrus token can currently be purchased for $0.0900 or 0.00001470 BTC on major cryptocurrency exchanges. In the last seven days, Darcrus has traded down 17.5% against the US dollar. Darcrus has a market capitalization of $1.22 million and approximately $0.00 worth of Darcrus was traded on exchanges in the last 24 hours.

Here’s how other cryptocurrencies have performed in the last 24 hours:

Get Darcrus alerts: XRP (XRP) traded down 6.7% against the dollar and now trades at $0.52 or 0.00008331 BTC. Ripple (XRP) traded down 0.5% against the dollar and now trades at $0.49 or 0.00007982 BTC. Stellar (XLM) traded down 0.9% against the dollar and now trades at $0.20 or 0.00003293 BTC. TRON (TRX) traded down 0.5% against the dollar and now trades at $0.0436 or 0.00000712 BTC. IOTA (MIOTA) traded up 1.4% against the dollar and now trades at $1.02 or 0.00016665 BTC. Tether (USDT) traded 0% lower against the dollar and now trades at $1.00 or 0.00016359 BTC. NEO (NEO) traded up 0.1% against the dollar and now trades at $33.73 or 0.00550840 BTC. Binance Coin (BNB) traded 2.5% lower against the dollar and now trades at $15.35 or 0.00250668 BTC. VeChain (VET) traded 1.9% lower against the dollar and now trades at $2.76 or 0.00045077 BTC. Ontology (ONT) traded 6.8% lower against the dollar and now trades at $5.01 or 0.00081889 BTC.

Darcrus Profile

Darcrus’ genesis date was December 12th, 2016. Darcrus’ total supply is 13,600,388 tokens. Darcrus’ official Twitter account is @darcrus. The official website for Darcrus is darcr.us.

Darcrus Token Trading

Darcrus can be bought or sold on these cryptocurrency exchanges: Waves Decentralized Exchange. It is usually not presently possible to purchase alternative cryptocurrencies such as Darcrus directly using U.S. dollars. Investors seeking to acquire Darcrus should first purchase Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as Changelly, GDAX or Coinbase. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase Darcrus using one of the exchanges listed above.

Top Biotech Stocks To Invest In Right Now

tags:AMGN,ALNY,ARQL,BIIB,

Investing in biotech and pharmaceuticals is always a bit of a wild card. The industry is often at the mercy of government regulators, and a clinical trial can always present unexpected challenges. When biotech and pharma stocks hit it big, however, it��s big news that often yields big returns. A lesser promoted biotech sector is the medical devices arena, which is hardly as sexy and fun to watch, and rarely receives the same sound-bite press coverage, but nonetheless can offer premium investment opportunities.

A case in point is Ventripoint Diagnostics Ltd. (OTCMKTS:VPTDF), the Toronto based company that recently received approval from Health Canada for its VMS-Plus �� heart imagining and diagnostic device. Following the announcement of Health Canada��s approval letter, Ventripoint shares rose almost 600% from $0.10 to $0.69.

Top Biotech Stocks To Invest In Right Now: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Chris Lange]

  Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.

• [By Logan Wallace]

  Intact Investment Management Inc. grew its holdings in Amgen (NASDAQ:AMGN) by 2,737.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,400 shares of the medical research company’s stock after purchasing an additional 43,800 shares during the period. Intact Investment Management Inc.’s holdings in Amgen were worth $7,739,000 as of its most recent filing with the Securities & Exchange Commission.

• [By Joseph Griffin]

  Field & Main Bank grew its stake in shares of Amgen (NASDAQ:AMGN) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $708,000 at the end of the most recent quarter.

• [By ]

  Celgene (CELG) : "I'd rather buy Amgen (AMGN) or Regeneron Pharmaceuticals (REGN) . I think Celgene overpaid for that acquisition a few years ago."

• [By Shane Hupp]

  Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79

Top Biotech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Brian Orelli]

  The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn't think a few months will really matter: "We don't really feel that's going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we're very well prepared to be ready to launch following approval."

• [By Keith Speights]

  I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  So, which biotech stocks should you consider buying in June? That's a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

• [By Keith Speights]

  It's not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum's market cap is less than $350 million while Alnylam's market cap is close to $10 billion.

• [By Joseph Griffin]

  BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

Top Biotech Stocks To Invest In Right Now: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

• [By Logan Wallace]

  BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

  A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

• [By Logan Wallace]

  ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

  Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

• [By Joseph Griffin]

  ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

Top Biotech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Shannon Jones]

  In this week's episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte's Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis' (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB)�might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.86 million shares from the previous 3.45 million. The stock recently traded at $287.00, within a 52-week range of $244.28 to $370.57.

• [By Todd Campbell]

  PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluating�risdiplam suggested it could mount a stiff challenge to�Biogen's (NASDAQ:BIIB)�and Ionis Pharmaceuticals'�(NASDAQ:IONS)�Spinraza�for the treatment of� spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis' (NYSE:NVS), and that therapy could become available as soon as 2019.�

• [By Dan Caplinger]

  Wall Street continued its downward streak on Monday, with the Dow Jones Industrial Average falling more than 100 points. Most major benchmarks fell more modestly, with a few actually poking into positive territory on the day. Trade-sensitive stocks were among the weakest as investors focused on uncertainty related to tariff disputes between the U.S. and China. But for some other companies, bad news of a different sort was responsible for the drops in their shares. Biogen (NASDAQ:BIIB), Baytex Energy (NYSE:BTE), and Catalyst Biosciences (NASDAQ:CBIO) were among the worst performers on the day. Here's why they did so poorly.

• [By Lisa Levin]

  Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.

  Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.

India Seeks `Responsible' OPEC Decision as Vienna Tensions Mount

LISTEN TO ARTICLE 1:49 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

India, the world’s third-largest oil consumer, expects a “responsible” approach from its suppliers as speculation mounts over whether OPEC and its allies will reach a deal to boost output at a meeting in Vienna this week.

India welcomes a proposal made by top producers Saudi Arabia and Russia to gradually ease the group’s supply curbs after prices rose to hit $80 a barrel last month, the South Asian nation’s oil minister, Dharmendra Pradhan, said in an interview at the Austrian capital. The Organization of the Petroleum Exporting Countries is heading into a contentious meeting on Friday, with Iran promising to block any decision to increase output.

“High prices are pinching our economy, pinching our country,” Pradhan said. “I think our supplying friends have taken notice of that.” India believes that $55 to $60 a barrel is a reasonable price level for now, he said. Brent crude, the benchmark for more than half the world’s oil, was trading near $75 a barrel on Wednesday.

For more on how rising oil is hurting India, click here

India and China are considering teaming up to buy U.S. supplies and counter OPEC’s dominance in the world’s biggest oil market. The two nations want to put pressure on the producer group to keep prices under control, an Indian government official said earlier this month.

Separately, the South Asian country also plans to seek exemptions to continue Iranian oil imports and make payments for purchases after America decided to reimpose sanctions on the Islamic Republic.

Pradhan didn’t say if India plans cuts in Iranian purchases. The nation, which relies on imports for almost 80 percent of its oil needs, is diversified in terms of supplies, with cargoes coming from the Middle East, Latin America and the U.S., he said.

“Due to our relationship with different stakeholders, we’re confident we don’t have to face any situation of scarcity,” Pradhan said.

Buy Music Broadcast; target of Rs 450: Dolat Capital

Dolat Capital's research report on Music Broadcast

MBL reports revenue growth of 14.1% YoY led by Phase III stations in terms of volume and by legacy stations in terms of yields. EBITDA margin improved 1100bps YoY to 36.0% is also helped by better collection as no provision for RDD had a positive impact of 200 bps on the margin; balance of the margin improvement (+900bps) was due to absence of losses/launch expenses of new stations.

Outlook

We believe higher ad. spends due to elections, introduction of MRUC rating and lower threat from digital vs other segments of media are some of the key triggers for performance of radio. We maintain our BUY recommendation and rollover to Jun��19 TP of ` 450 based on 17x one yr. fwd. EV/EBITDA.

For all recommendations report,�click here

Disclaimer:�The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on May 31, 2018 03:47 pm